ClinicalTrials.gg
RecruitingNCT07555574Updated Apr 29, 2026

Defining Retinal Structures Using Hyperspectral Retinal Imaging

An interventional study of Hyperspectral camera in Age-Related Macular Degeneration, Diabetic Retinopathy and Glaucoma, sponsored by Center for Eye Research Australia. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Center for Eye Research Australia · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Jan 2025, registered Apr 2026).
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Macular Degeneration with a site in Australia — 17 open to participants now, 22 under way, 7 of them phase 3. Macular Degeneration · Australia.

Planned enrollment
5th of 66
1,000 · median 280
Started
2025
with 7 others
No phase
5 of 77
2 open now
Primary completion
2028-12
later than 15 of 21 live
Registered
75th of 77
by date
Lead sponsor
6 of 77
Center for Eye Research Australia

Among the 77 studies in Macular Degeneration with a site in Australia, this one is the 5th largest by planned enrollment of the 66 interventional ones that give a count, is one of 8 that started in 2025, is one of 5 with no phase, reaches primary completion later than 15 of the 21 other live ones, and was the 75th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

17 of the 77 studies in Macular Degeneration with a site in Australia are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Macular Degeneration with a site in Australia, or all of them as a file.
02

Study summary

This study evaluates hyperspectral retinal imaging as a novel, non-invasive imaging technique to characterise retinal and optic nerve structures in healthy individuals and patients with eye disease. Hyperspectral imaging captures retinal data across multiple wavelengths to generate detailed spectral information that may reveal features not visible with conventional retinal photography.

Approximately 1000 participants will undergo multi-modal ophthalmic imaging in Melbourne, Australia, including hyperspectral imaging, OCT, fundus photography, and related tests. The study aims to compare hyperspectral imaging with standard imaging methods and assess its ability to identify retinal biomarkers associated with diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration.

Read the detailed description

This is a investigator-initiated imaging study assessing hyperspectral retinal imaging (HSI) for characterising retinal and optic nerve structures in healthy and diseased eyes.

HSI acquires retinal images across multiple wavelengths (>25 bands), producing a spectral "hypercube" containing spatial and spectral information for each pixel. This provides more detailed tissue information than conventional colour fundus photography.

Approximately 1000 participants will be recruited from ophthalmology clinics in Melbourne. All participants will undergo standard ophthalmic assessment and hyperspectral retinal imaging using the Optina device and a CERA prototype camera.

Hyperspectral images will be processed with registration and spectral normalisation to extract pixel-level reflectance signatures. These data will be analysed using statistical and machine learning methods and compared with established imaging biomarkers to evaluate their ability to distinguish disease states.

03

Conditions studied

  • Age-Related Macular Degeneration
  • Diabetic Retinopathy
  • Glaucoma
  • Retinal Diseases
  • Healthy Volunteers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years and older
  • Able to provide
  • Willing and able to attend a study visit at the Centre for Eye Research Australia
  • Participants with diagnosed retinal or optic nerve disease (e.g., diabetic retinopathy, glaucoma, age-related macular degeneration)
  • Age- and sex-matched healthy control participants without known retinal or optic nerve disease

Exclusion criteria

Exclusion Criteria:

  • Inability to provide
  • Ocular conditions preventing adequate retinal imaging (e.g., dense cataract, severe corneal opacity, vitreous haemorrhage)
  • Known to pharmacological pupil dilation
  • History of narrow anterior chamber angle or risk of angle closure glaucoma where dilation is considered unsafe
  • Any condition that, in the investigator's opinion, would compromise participant safety or image quality
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Hyperspectral retinal imaging

    Participants undergo non-invasive hyperspectral retinal imaging as part of a multi-modal ophthalmic imaging protocol. Hyperspectral imaging is performed using the Optina Diagnostics Metabolic Hyperspectral Retinal Camera and/or a prototype hyperspectral camera developed at the Centre for Eye Research Australia. The intervention involves sequential retinal imaging across multiple wavelengths (\>25 spectral bands) following standard dilated fundus examination. Imaging is similar to conventional retinal photography but provides additional spectral information for each retinal pixel. Participants also undergo standard clinical imaging (including OCT, OCT angiography, fundus photography, and autofluorescence) for comparison. The study is observational and non-therapeutic, with hyperspectral imaging used solely for research analysis of retinal structure and spectral biomarkers.

    Device: Hyperspectral camera

Interventions

  • DeviceHyperspectral camera

    Hyperspectral imaging is performed with the Metabolic Hyperspectral Retinal Camera (Optina Diagnostic, Montreal, Canada) and a prototype camera developed by researchers at the Centre for Eye Research Australia (CERA). The Metabolic Hyperspectral Retinal Camera is similar to a typical fundus imager but it incorporates a tunable light source which is able to transmit safe light levels within a wavelength range covering the visible to near infrared with a narrow bandwidth (\< 3nm). This instrument is capable of imaging a 26° field-of-view of retina at 90 wavelengths in less than a second, thus minimizing discomfort and limiting the influence of eye movements. The hyperspectral camera developed by CERA researchers is a non-mydriatic fundus camera that uses light emitting diodes (LEDs) and an optical variable bandpass filter to tune the illumination wavelengths.

06

What researchers measure

Primary outcomes

  1. Diagnostic performance of hyperspectral imaging-derived spectral score for detection of retinal disease

    To assess the ability of hyperspectral retinal imaging to distinguish between healthy and diseased eyes using a quantitative hyperspectral spectral score derived from image analysis algorithms (e.g., DROP-D or machine learning models). Diagnostic performance will be evaluated against clinical diagnosis using receiver operating characteristic (ROC) analysis.

    Time frame: During study visit (baseline data collection); analyses performed after completion of participant recruitment and imaging dataset acquisition

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — The plan for sharing individual participant data (IPD) has not yet been finalised. This is a multi-modal imaging study involving large hyperspectral and ophthalmic imaging datasets, and decisions regarding data sharing will depend on completion of primary analyses, data governance requirements, and ethical approvals. The feasibility of appropriate de-identification and secure sharing mechanisms is under review.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2028, 47 months after the start.

Of 105 non-industry interventional studies with no phase under Macular Degeneration, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 47 months is above that.

Counting every sponsor, half of 133 studies reached it within 37 months; a quarter within 17 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 29, 2026
StartActual
Jan 1, 2025
Primary completionEst.
Dec 30, 2028
CompletionEst.
Dec 30, 2028
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07555574
Lead sponsor
Center for Eye Research Australia
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
Jan 1, 2025
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Apr 29, 2026

Study contacts

Darvy Dang
Contact
darvy.dang@unimelb.edu.au
+61 3 9959 0102

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion